Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
2022 | Sanofi profit gain beats market view on bestseller drug Dupixent | RE |
2022 | Sanofi to float drug ingredients manufacturing business on May 6 | RE |
Financials (USD)
Sales 2008 | 22.12K | Sales 2009 | 5.22K | Capitalization | 563K |
---|---|---|---|---|---|
Net income 2008 | - | Net income 2009 | - | EV / Sales 2008 | 33.3 x |
Net Debt 2008 | 399K | Net Debt 2009 | 673K | EV / Sales 2009 | 237 x |
P/E ratio 2008 |
-0.98
x | P/E ratio 2009 |
-1.34
x | Employees | 2 |
Yield 2008 * |
-
| Yield 2009 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald S. Tucker
CEO | Chief Executive Officer | 84 | 97-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ronald S. Tucker
CEO | Chief Executive Officer | 84 | 97-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 0.000001 | +∞% | 200 |
Delayed Quote OTC Markets, April 19, 2024 at 10:24 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
0.00% | 20 | |
+21.33% | 52.84B | |
+15.59% | 6.71B | |
-21.05% | 768M | |
+132.06% | 594M | |
+240.45% | 468M | |
-32.35% | 409M | |
-.--% | 116M | |
-18.64% | 109M | |
-8.89% | 109M |
- Stock Market
- Equities
- EPOR Stock